NCT03803761: Copanlisib and Fulvestrant in Treating Postmenopausal Patients With ER+ and HER2- Metastatic Breast Cancer Progressing After Aromatase and CDK 4/6 Inhibitors Treatment

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, PTEN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have progressed on combination therapy with an AI & CDK 4/6 inhibitor
Exclusions: Patients with symptomatic untreated brain metastases- see trial for details; Patients who have received more than 2 prior lines of chemotherapy in the metastatic setting

Comments are closed.

Up ↑